Unless the pharmaceutical industry manages product lifecycle data holistically in 2016, companies’ ability to achieve regulatory compliance and maintain speed to market will be compromised, warns Mark Evenepoel, Group, Amplexor Life Sciences
Of all the challenges facing life sciences organisations in 2016, it is the conflicting priorities of regulatory compliance and global competitive pressure that will be the most demanding. That’s unless companies find a new, more holistic way to manage their product lifecycle data right across their operations – from R&D to market distribution.